Abstracts tagged "Atherosclerosis"

Abstract Number: 1848 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Risk Factors in Adults with Juvenile Idiopathic Arthritis in Sustained Remission
Ivan Arias de la Rosa¹, Inmaculada Concepcion Aranda-Valera², Rosa Roldan², Maria Carmen Abalos-Aguilera¹, Maria Dolores de la Rosa-Garrido², Yolanda Jiménez-Gómez³, Carlos Perez-Sanchez³, Alejandro Escudero-Contreras¹, Chary Lopez-Pedrera², Eduardo Collantes-Estévez³ and Nuria Barbarroja³, ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is one of the more common chronic diseases of childhood that often persists into adulthood and can result in significant…
Abstract Number: 2816 • 2018 ACR/ARHP Annual Meeting
Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
Michelle J. Ormseth¹, Joseph F. Solus¹, Quanhu Sheng¹, Fei Ye¹, Yan Guo¹, Qiong Wu¹, Annette M. Oeser¹, Ryan Allen¹, Paolo Raggi², Kasey Vickers¹ and C Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), regulate gene expression and can be used as biomarkers of disease. Patients with rheumatoid arthritis (RA)…
Abstract Number: 68 • 2018 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Identifies rs116199914 As an Intergenic Variant Associated with Carotid Intima-Media Thickness in Spanish Patients with Rheumatoid Arthritis
Raquel Lopez-Mejías¹, Fernanda Genre¹, Sara Remuzgo-Martínez¹, David Carmona^2,3, Verónica Pulito-Cueto¹, Carlos González-Juanatey⁴, Alfonso Corrales¹, Esther Vicente⁵, Jose A. Miranda-Filloy⁶, Beatriz-Segura Tejera⁷, Marco A. Ramírez Huaranga⁸, Verónica Mijares¹, Leticia Lera-Gomez¹, Ricardo Blanco¹, Montserrat Robustillo-Villarino⁹, Javier Rodríguez-Carrio¹⁰, Ana Suárez¹⁰, Mercedes Alperi-López¹¹, Francisco Javier Ballina-García¹², Francisco Javier López Longo¹³, Francisco Javier Narváez¹⁴, Juan José Alegre⁹, Antonio Mera¹⁵, Eva Perez Pampín¹⁶, Antonio Gonzalez¹⁷, Enrique Raya Álvarez¹⁸, Chary López-Pedrera¹⁹, Carmen Gomez Vaquero¹⁴, Alejandro Balsa²⁰, Dora Pascual-Salcedo²⁰, Patricia Carreira²¹, Isidoro Gonzalez-Alvaro⁵, Luis Rodriguez Rodriguez²², Benjamin Fernandez Gutierrez²², Ivan Ferraz-Amaro²³, Santos Castañeda²⁴, Javier Martin³, Javier Llorca²⁵ and Miguel Angel González-Gay^1,26,27, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain, ³Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, ⁴Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁵Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁶Rheumatology Department, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁷Rheumatology Division, Hospital Insular de Gran Canaria, Las Palmas, Spain, ⁸Rheumatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ⁹Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁰Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ¹¹Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ¹²Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹³Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁴Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ¹⁵Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁶Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁷Laboratorio Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹⁸Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²⁰Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ²¹Servicio de Reumatología, Hospital Universitario, Madrid, Spain, ²²Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ²³Rheumatology Division, Hospital Insular de Gran Canaria, La Laguna, Spain, ²⁴Rheumatology, Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ²⁵School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ²⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, ²⁷Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Cardiovascular (CV) disease is the most common cause of morbidity and mortality in patients with rheumatoid arthritis (RA) [1, 2]. Traditional CV risk factors…
Abstract Number: 2818 • 2018 ACR/ARHP Annual Meeting
Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Panagiota Anyfanti¹, Eugenia Gkaliagkousi¹, Areti Triantafyllou¹, Eleni Gavriilaki¹, Panagiotis Dolgyras¹, Sophia Chatzimichailidou², Vasiliki Galanopoulou³, Stella Douma¹ and Spyros Aslanidis², ¹3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ²Rheumatology Department-2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ³Rheumatology Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece
Background/Purpose: Galectin-3 has emerged as a promising novel biomarker of cardiovascular fibrosis, that can improve cardiovascular risk stratification in high-risk populations. Rheumatoid arthritis (RA) is…
Abstract Number: 644 • 2017 ACR/ARHP Annual Meeting
Association of Osteonectin, Osteopontin and Osteocalcin with Inflammation and Cardiovascular Risk in Patients with Axial Spondyloarthritis
Fernanda Genre¹, Javier Rueda-Gotor², Juan Irure-Ventura³, Sara Remuzgo-Martínez¹, Alfonso Corrales¹, Begoña Ubilla¹, Veronica Mijares¹, Carlos Fernández-Díaz¹, Virginia Portilla¹, Ricardo Blanco¹, Javier Llorca⁴, J. Gonzalo Ocejo-Vinyals³, Raquel López-Mejías¹ and Miguel Angel González-Gay⁵, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Immunology Division, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain
Background/Purpose: A higher incidence of cardiovascular (CV) risk factors and atherosclerosis has been reported in axial spondyloarthritis (axSpA) patients1. Since axSpA (particularly AS) is an…
Abstract Number: 899 • 2017 ACR/ARHP Annual Meeting
Neutrophil Gene Signature and Low Density Granulocyte Subsets Associate with Coronary Plaque Burden and Vascular Inflammation in Systemic Lupus Erythematosus
Philip Carlucci¹, Monica Purmalek¹, Simantini Sakhardande¹, Yenealem Temesgen-Oyelakin¹, Amit K. Dey², Aditya A. Joshi², Joseph B. Lerman³, Alice Fike¹, Michael Davis⁴, Hong-Wei Sun¹, Jonathan H. Chung², Martin P. Playford², Pragnesh Mistry¹, Gustavo Gutierrez-Cruz¹, Stefania Dell'Orso¹, Faiza Naz¹, Heather Teague², Zerai G. Manna⁵, Peter C. Grayson¹, Mohammad Naqi¹, Marcus Chen², Sarfaraz A. Hasni¹, Nehal N. Mehta² and Mariana J. Kaplan¹, ¹NIH/NIAMS, Bethesda, MD, ²NIH/NHLBI, Bethesda, MD, ³NIH/CC, Bethesda, MD, ⁴NIH/NIAMS, Bethesda, IA, ⁵NIH/NIAMS, Bethesda, MD, Afghanistan
Background/Purpose: Systemic lupus erythematosus (SLE) increases a young woman’s risk of myocardial infarction by up to 50-fold. This marked increase in cardiovascular disease (CVD) risk…
Abstract Number: 964 • 2017 ACR/ARHP Annual Meeting
Atherogenic Potency of Plasma from Persons with Autoimmune Rheumatic Disorders: Comparative Effects on Cholesterol Flux in Human Macrophages
Andrew Maidhof¹, Allison B. Reiss^1,2, Lora J. Kasselman², Elise Belilos¹, Kristina Belostocki¹, Gary Rosenblum¹, Lois Bonnetti¹, Melissa Fazzari², Joshua DeLeon¹ and Steven E. Carsons^1,2, ¹NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, ²NYU Winthrop University Hospital, Winthrop Research Institute, Mineola, NY
Background/Purpose: Although the risk of atherosclerotic cardiovascular disease and abnormalities in cholesterol transport have been demonstrated in rheumatoid arthritis (RA), lupus (SLE) and, to a…
Abstract Number: 1484 • 2017 ACR/ARHP Annual Meeting
Association between Primary Sjogren’s Syndrome, Arterial Stiffness and Subclinical Atherosclerosis: A Systematic Review and Meta-Analysis
Wai Chung Yong, Anawin Sanguankeo and Sikarin Upala, Bassett Medical Center, Cooperstown, NY
AbstractBackground/Purpose: In rheumatoid arthritis and systemic lupus erythematosus, cardiovascular disease is frequently a major cause of mortality or morbidity. Studies have shown that acute systemic…
Abstract Number: 1585 • 2017 ACR/ARHP Annual Meeting
Role of Corticosteroids in Subclinical Atherosclerosis in SLE: A Systematic Review and Meta-Analysis
Ehsan Rajabirostami¹, Kam Newman², Sreelakshmi Panginikkod¹, Shahrzad Mohammadiankhansari¹, Nader Mehri³, Roshanak Habibi⁴ and Manish Jain⁵, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Rheumatology, Eisenhower Medical Center, Rancho Mirage, CA, ³Social Gerontology, Miami University, Oxford, OH, ⁴Presence Saint Francis Hospital, Evanston, IL, ⁵Rheumatology, Presence Saint Francis Hospital, Evanston, IL
Background/Purpose: Atherosclerosis in SLE results from a complex interplay between traditional risk factors, SLE-specific factors, chronic inflammation and multifaceted effects of SLE therapeutics. In particular,…
Abstract Number: 1609 • 2017 ACR/ARHP Annual Meeting
Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus
Nathan Stein¹, Joseph F. Solus¹, Annette M. Oeser¹, Paolo Raggi², C Michael Stein¹ and Michelle J. Ormseth³, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada, ³Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Coronary atherosclerosis increases with age but is more prevalent in patients with systemic lupus erythematosus (SLE) independent of chronological age; this increased prevalence has…
Abstract Number: 1674 • 2017 ACR/ARHP Annual Meeting
Combining Medications That Lower Systemic Oxidative Stress Is Associated with Less Atherosclerosis in Systemic Lupus Erythematosus
Jim C. Oates, Medical Service, Ralph H. Johnson VA Medical Center, Charleston, SC; Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: No single medication has been demonstrated as effective in reducing atherosclerosis or cardiovascular events in systemic lupus erythematosus (SLE), possibly due to the…
Abstract Number: 2357 • 2017 ACR/ARHP Annual Meeting
Retinal Vessel Morphological Associations with Systemic Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Panagiota Anyfanti¹, Areti Triantafyllou¹, Eugenia Gkaliagkousi¹, Xenophon Zabulis², Stella Douma¹ and Spyros Aslanidis³, ¹3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ²Institute of Computer Science, Foundation for Research and Technology-Hellas (FORTH), Heraklion, Greece, Heraklion, Greece, ³Rheumatology Department-2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece
Background/Purpose: Rheumatoid arthritis (RA) is associated with a chronic inflammatory state, accelerated atherosclerosis and excess cardiovascular risk. Quantification of morphological changes in the retinal microvasculature…
Abstract Number: 2369 • 2017 ACR/ARHP Annual Meeting
Relationship of Bone Mineral Density and Inflammatory Burden with Carotid Plaque Formation in Rheumatoid Arthritis: A 5-Year Prospective Study
Na Ri Kim, Jong Wan Kang, Jung Su Eun, Ji Hun Kim, Jin Young Kang, Gi Bum Bae, Sang Jin Lee, Eon Jeong Nam and Young Mo Kang, Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease. The incidence of the cardiovascular (CV) disease is significantly increased in patients with RA…
Abstract Number: 2401 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis with Kidney Dysfunction Contributes to Higher Risk of Cardiovascular Disease Development
Suad Hannawi¹ and Issa Al Salmi², ¹Rheumatology, Asst.Prof, Dubai, United Arab Emirates, ²Prof, Muscat, Oman
Background/Purpose: Reduced kidney function render patients with RA rheumatoid arthritis (RA), have an increased risk of cardtiovascular disease (CVD), particulary ischemic heart disease (IHD). This…
Abstract Number: 2527 • 2017 ACR/ARHP Annual Meeting
Increased Prevalence of Subclinical Atherosclerosis in Moderate-Severe Plaque Psoriasis Patients
Nuria Vegas-Revenga¹, José Luis Martín-Varillas¹, Susana Armesto², Marcos A González- López³, Virginia Portilla², Patricia Fuentevilla¹, Javier Rueda-Gotor², Carlos Fernández-Díaz¹, Lucia C. Domínguez-Casas¹, Belén Atienza-Mateo¹, Jose L. Hernández⁴, Ricardo Blanco¹, Miguel Angel González-Gay¹ and Alfonso Corrales¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Surrogate markers of subclinical atherosclerosis and cardiovascular (CV) mortality such as carotid plaques (CP), arterial stiffness (AS) and carotid intima-media thickness (c-IMT), have been…

« Previous Page
1
…
5
6
7
8
9
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].